Financial Data and Key Metrics Changes - For Q4 2024, net revenue from continuing operations was 10.4million,representingan11.638 million, with a net loss of approximately 6.5millionfortheyear[45][46]−TotaloperatingexpensesforQ4were12.3 million, down from 15.5millionintheprioryear[45]BusinessLineDataandKeyMetricsChanges−NetrevenuebyproductforQ42024included4.4 million for Kristalose, 2.4millionforSancuso,2.1 million for Vibativ, and 1.4millionforCaldolor[44]−Fullyearproductrevenuetotaled15.3 million for Kristalose, 9millionforSancuso,6.9 million for Vibativ, and 5millionforCaldolor[45]MarketDataandKeyMetricsChanges−VibativreceivedapprovalinChina,expandingitsinternationalbusiness,andshipmentsbegantoSaudiArabia[14]−KristalosesawgrowthduetonewMedicaidcoverageinseveralstates,includingVirginia,Louisiana,andMaine[23]CompanyStrategyandDevelopmentDirection−Thecompanyaimstoacquireandcommercializeaportfolioofbrandedpharmaceuticalswhileexpandingitssalesorganizationanddevelopmentpipeline[11][12]−CumberlandEmergingTechnologies(CET)isajointinitiativewithVanderbiltUniversitytoenhancethedevelopmentpipeline[12]Management′sCommentsonOperatingEnvironmentandFutureOutlook−Managementexpressedoptimismabouttheprogressofclinicalstudiesforifetrobananditspotentialtobenefitmanypatients[54]−Thecompanyexpectsdouble−digitrevenuegrowthandpositivecashflowfromoperationsintheupcomingyear[57]OtherImportantInformation−Thecompanycontinuestohold53 million in tax net operating loss carryforwards, primarily from prior stock option exercises [52] - Cumberland has an active acquisition initiative to seek additional FDA-approved brands [56] Q&A Session Summary - No questions were raised during the Q&A session, and management encouraged private discussions with shareholders if desired [60]
